- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02062281
Study of Evaluating Safety and Immunogenicity of 23-Valent Pneumococcal Polysaccharide Vaccine With Influenza Vaccine in Children and Adults
February 12, 2014 updated by: Jiangsu Province Centers for Disease Control and Prevention
A Phase 4, Randomized, Single-blind Trial to Evaluate Safety and Immunogenicity of a 23-Valent Pneumococcal Polysaccharide Vaccine When Administered Simultaneously With Trivalent Inactivated Influenza Vaccine in Healthy Children Aged 3-7years and Healthy Adults 65 Aged 50-65years.
The 23-valent pneumococcal Polysaccharide vaccine (23vPPV) has been developed for children and adults to prevent pneumococcal diseases such as pneumonia (inflammation of the lungs), meningitis (inflammation of the brain lining), and septicemia (blood poisoning) since 2006 in China.
Also, the trivalent influenza vaccine (TIV) is frequently administered to the children and adults.
The main objective of this study is to show that both vaccines can safely be administered together without affecting the immune response of protecting against disease.
Study Overview
Status
Completed
Conditions
Study Type
Interventional
Enrollment (Actual)
2225
Phase
- Phase 4
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
Jiangsu
-
Zhenjiang, Jiangsu, China, 212200
- Yangzhong Center for Disease Control and Prevention
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
3 years to 65 years (ADULT, OLDER_ADULT, CHILD)
Accepts Healthy Volunteers
Yes
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Generally healthy male or female, for adults 50-65 years of age, for children 3-7 years of age.
- Available for the duration of the trial - approximately 2 months.
- No history of severe adverse reaction associated with a vaccine.
Exclusion Criteria:
- Subject that has a medical history of any of the following: allergic history, or allergic to any ingredient of vaccine, such as egg, egg protein, etc.
- Serious adverse reactions to vaccines such as anaphylaxis, hives, respiratory difficulty, angioedema, or abdominal pain.
- Autoimmune disease or immunodeficiency.
- Asthma that is unstable or required emergent care, hospitalization or intubation during the past two years or that required the use of oral or intravenous corticosteroids.
- Diabetes mellitus (type I or II), with the exception of gestational diabetes History of thyroidectomy or thyroid disease that required medication within the past 12 months.
- Serious angioedema episodes within the previous 3 years or requiring medication in the previous two years.
- Bleeding disorder diagnosed by a doctor (e.g. factor deficiency, coagulopathy, or platelet disorder requiring special precautions) or significant bruising or bleeding difficulties with IM injections or blood draws.
- Any history of immunosuppressive medications or cytotoxic medications or inhaled corticosteroids within the past six months (with the exception of corticosteroid nasal spray for allergic rhinitis or topical corticosteroids for an acute uncomplicated dermatitis)
- History of any blood products or seasonal influenza vaccine administration within 3 months before the dosing.
- Administration of any other investigational research agents within 30 days before the dosing.
- Administration of any live attenuated vaccine within 30 days before the dosing Administration of subunit or inactivated vaccines, e.g., pneumococcal vaccine, or allergy treatment with antigen injections, within 14 days before the dosing.
- Axillary temperature > 37.0 centigrade at the time of dosing.
- Psychiatric condition that precludes compliance with the protocol.
- Any medical, psychiatric, social condition, occupational reason or other responsibility that, in the judgment of the investigator, is a contraindication to protocol participation or impairs a volunteer's ability to give informed consent
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: PREVENTION
- Allocation: RANDOMIZED
- Interventional Model: PARALLEL
- Masking: SINGLE
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
ACTIVE_COMPARATOR: 23-valent Pneumococcal Polysaccharide vaccine
0.5ml 23-valent pneumococcal Polysaccharide vaccine made by Chengdu Institute of Biological Products Co.,Ltd. lot number: 20130106-1, duration:JAN,17,2015. |
Single 0.5ml 23-valent pneumococcal polysaccharide vaccine was administered intramuscularly (IM)
|
ACTIVE_COMPARATOR: Trivalent Influenza Vaccine
0.5ml trivalent influenza vaccine made by Shanghai Institute of Biological Products Co.,Ltd. lot number:20130713, duration:Jul,1,2014. |
Single 0.5ml trivalent influenza vaccine was administered IM
|
EXPERIMENTAL: 23vPPV+TIV
|
Single 0.5 ml 23-valent pneumococcal polysaccharide vaccine (23vPPV) and a single 0.5 ml trivalent inactivated influenza vaccine (TIV) were administered IM, in one day.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Immunogenicity of 23vPPV
Time Frame: 1 month after 23vPPV vaccination
|
IgG GMC measured by enzyme-linked immunosorbent assay (ELISA) and expressed in micrograms per mL (mcg/mL) for serotypes 1,2,5,6B,14,19F,23F,which were frequently detected in patients in Chinese.
|
1 month after 23vPPV vaccination
|
Immunogenicity of TIV
Time Frame: 1 month after TIV vaccination
|
Percentage of participants achieving at Least a 4-fold Increase in the Titer of the Standard Hemagglutination Inhibition Assay (HAI)
|
1 month after TIV vaccination
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
adverse events following the immunization (AEFI)
Time Frame: 28 days after 23vPPV and TIV vaccination
|
28 days after 23vPPV and TIV vaccination
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Collaborators
Investigators
- Principal Investigator: ma fubao, doctor, Jiangsu CDC
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
November 1, 2013
Primary Completion (ACTUAL)
December 1, 2013
Study Completion (ACTUAL)
January 1, 2014
Study Registration Dates
First Submitted
February 12, 2014
First Submitted That Met QC Criteria
February 12, 2014
First Posted (ESTIMATE)
February 13, 2014
Study Record Updates
Last Update Posted (ESTIMATE)
February 13, 2014
Last Update Submitted That Met QC Criteria
February 12, 2014
Last Verified
February 1, 2014
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
- RNA Virus Infections
- Virus Diseases
- Infections
- Respiratory Tract Infections
- Respiratory Tract Diseases
- Bacterial Infections
- Bacterial Infections and Mycoses
- Streptococcal Infections
- Gram-Positive Bacterial Infections
- Orthomyxoviridae Infections
- Pneumococcal Infections
- Influenza, Human
- Physiological Effects of Drugs
- Immunologic Factors
- Vaccines
- Heptavalent Pneumococcal Conjugate Vaccine
Other Study ID Numbers
- JSEPI-002
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Influenza
-
Novartis VaccinesCompletedInfluenza | Seasonal Influenza | Human Influenza | Influenza Due to Unspecified Influenza VirusBelgium
-
Gamaleya Research Institute of Epidemiology and...CompletedInfluenza A | Influenza A Virus Infection | Influenza Epidemic | Influenza H5N1Russian Federation
-
Vanderbilt University Medical CenterHuman Vaccines ProjectCompletedVaccine Reaction | Influenza | Influenza, Human | Influenza A | Influenza Type B | Influenza A H3N2 | Influenza A H1N1United States
-
National Institute of Allergy and Infectious Diseases...Completed
-
National Institute of Allergy and Infectious Diseases...Completed
-
National Institute of Allergy and Infectious Diseases...CompletedInfluenza Immunisation | Avian InfluenzaUnited States
-
National Institute of Allergy and Infectious Diseases...CompletedInfluenza | Influenza Immunisation | Avian InfluenzaUnited States
-
National Institute of Allergy and Infectious Diseases...CompletedInfluenza Immunisation | Avian InfluenzaUnited States
-
National Institute of Allergy and Infectious Diseases...National Institutes of Health (NIH)CompletedInfluenza AUnited States
-
National Institute of Allergy and Infectious Diseases...CompletedInfluenza Immunisation | Avian InfluenzaUnited States
Clinical Trials on 23-valent pneumococcal polysaccharide vaccine
-
Beijing Zhifei Lvzhu Biopharmaceutical Co., LtdActive, not recruiting
-
Seema BhatRecruitingChronic Lymphocytic Leukemia | Small Lymphocytic LymphomaUnited States
-
University of UtahNational Cancer Institute (NCI)RecruitingChronic Lymphocytic Leukemia | Small Lymphocytic LymphomaUnited States
-
Wyeth is now a wholly owned subsidiary of PfizerCompletedPneumococcal VaccinesUnited States
-
Sinovac Biotech Co., LtdCompletedInfluenza and PneumoniaChina
-
Aimei Vacin BioPharm (Zhejiang) Co., Ltd.Recruiting
-
VA Sierra Nevada Health Care SystemMerck Sharp & Dohme LLCNot yet recruitingImmunosuppression | Pneumococcal Vaccines
-
PfizerCompletedPneumococcal InfectionsUnited States
-
PATHCompleted
-
University of MelbourneNational Health and Medical Research Council, Australia; Menzies School of...UnknownPneumococcal Infections | Tympanic Membrane Perforation | Acute Otitis Media | Middle Ear EffusionAustralia